IceCure Medical Stock Rockets After Commercial Update Shows Rapid ProSense Adoption
IceCure Medical shares jumped sharply in pre-market trading after the company reported a 70% increase in its U.S. active install base for the ProSense breast cancer cryoablation system since the device received FDA marketing authorization in October 2025. The update noted accelerating procedures across major U.S. metropolitan markets and rising ado…